Sizing up the mismatch between health outcomes of minorities and representation in clinical trials

Patients in racial and ethnic minority groups are more likely to die from several diseases than white patients, yet they’ve been under-represented in most clinical trials supporting recent drug approvals in the indications.

Data from HHS’s Office of Minority Health highlight half a dozen diseases where minority groups are more than twice as likely to die than non-Hispanic whites, with Blacks and American Indian or Alaska Natives showing that level of disparity across multiple diseases (see “Biopharmas Must Address the Reality of Racial Disparities in Health Outcomes”). ...